Overview
Founded in 2008 and listed on NASDAQ and Euronext Brussels, argenx is one of Belgium's most successful biotech companies by market capitalization. The company focuses on developing treatments for severe autoimmune diseases using its proprietary antibody technology platform, SIMPLE Antibody. Its lead product, efgartigimod, is approved in multiple markets for myasthenia gravis and several other indications.
Media & appearances
- De TijdYouTube28/07 | Politie zet burgerpersoneel volop in voor gevoelige taken | Niet alleen klimaatveranderin...Belgian-Dutch biotech acquiring US peer Forte Biosciences for $2.2 billion to diversify beyond blockbuster drug Vyvgart before its patent expires.
- De TijdYouTube23/07 | Brusselse beurs wordt minder populair | Alphabet klopt verwachtingen, Tesla onder de lat ...The other Belgian star stock still attracting trading interest, benefiting from ETF flows tied to the Euro Stoxx 50.
- De TijdYouTube20/07 | Weekvooruitblik met columnist Rik Van Cauwelaert | Politiek geladen 21 juli | Nieuwe Brit...Belgian biotech and Bel 20 heavyweight reporting Thursday morning, with its golden product Vyvgart.
- De TijdYouTubeBeursvoyeurs Zomer | Serge Mampaey (De Tijd): 'Jim Cramer bracht Wall Street naar de huiskamer'The one Brussels biotech that would appeal to Cramer, since he only tolerates absolute top biotech players.
- De TijdYouTubeSophie Stegen (Euronext Brussel): ‘Een ETF op de Bel20 zal er pas komen wanneer grote beleggers e...Bel20 pharma heavyweight and Euronext Brussels client; now also has mini options (10 shares) available.
- De TijdYouTubeAlexander Roose (Argenta): 'Ik zie vandaag mooie kansen in de sector van de voedingsingrediënten'One of Belgium's two big pharma names with a phenomenal track record, though less diversified and facing potential disruption from Chinese pharma research.
Stated facts & numbers
- Argenx pays $2.2 billion for Forte Biosciences, a US biotech with no drug on the market; its key asset FB-102 is still in early testing phase.De Tijd 2026-07-280:09:14
- Vyvgart has become a commercial machine generating billions of euros per year for Argenx.De Tijd 2026-07-280:10:45
- Alphabet and Tesla report earnings Wednesday, SAP Thursday, Volkswagen Friday, and Argenx Thursday morning; Sofina reports half-year results on 2 September.De Tijd 2026-07-200:12:54
- Euronext mini options require only 10 shares (versus 100 for standard contracts) and exist on ASML, Argenx, UCB and — exceptionally at 1 share — Lotus Bakeries.De Tijd 2026-06-240:41:09
Funding & milestones
1 events found for argenx · 2026
AcquisitionDetailsAmount not disclosed
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Key people
In the news
- Congenital myasthenic syndromes (CMS) are rare, complex and can present differently from person to person, which means they can sometimes be overlooked. With significant unmet need remaining, greater understanding of CMS can help inform continued research and innovation. Learn more about what makes CMS so complex and the science behind these conditions: https://bit.ly/4zzqQno #EntrepreneurialScience
- Meet the team helping keep quality and supply on track for patients. Nicola Dietmann, Head of Product Quality Batch Release, leads with a team-first mindset. She prioritizes collaboration across teams to help ensure compliant materials are released and available for patients. Even when timelines move quickly, staying connected helps keep the work moving efficiently. At argenx, co-creation is central to how work gets done. Follow along to meet more of the people behind our work. #EntrepreneurialScience #PatientSupport
- Collaboration doesn’t stop at discovery. Through our Immunology Innovation Program (IIP), we work side-by-side with academic scientists, bringing together expertise in disease biology, antibody engineering and clinical development to help advance promising research toward potential medicines for patients. In a new article developed with Nature Partnerships, we explore how this approach to co-creation is helping advance immunology research, including the development of empasiprubart for multifocal motor neuropathy (MMN). Read the
- Bringing both Biotech and the Tech industry together at the Tech x Bio night in Ghent was a smart move. It was interesting to see talks from argenx and Orionis Biosciences outside the "normal scientific conference" setting that I am used to. Vice-versa it was also inspiring to see the tech-talks from Aikido Security and TechWolf in their kind of "natural Wintercircus" habitat. It's now the second time that I see Jeroen Van Hautte 🐺 showing live Claude Code sessions and I love the style 😁 The ambition to scale globally from day
- Opleidingsbudget 2027: heb je een NXT-lidmaatschap al overwogen? ++ In veel organisaties worden de budgetten voor volgend jaar nu vastgelegd, ook voor je eigen professionele ontwikkeling als HR-professional. Daarom zetten we nog eens op een rij wat het NXT-lidmaatschap inhoudt: ✅ 4 Bedrijfsbezoeken ✅ gratis deelname aan 2 connect & learn events (t.w.v. € 250 per event) ✅ 2 exclusieve NXT-inspiratieavonden (incl bring a friend) ✅ 4 keer per jaar het #ZigZagHR Bookazine ✅ Toegang tot het volledige digitale archief ✅ Korting
- We're presenting new data from the Phase 3 ALKIVIA study in autoimmune myositis as a late-breaking oral presentation at the American College of Rheumatology Convergence next month. We look forward to joining the rheumatology community in sharing new research, ideas and perspectives shaping the field at #ACR26. Explore more: https://bit.ly/4dUne6B #EntrepreneurialScience
- Q3 2026 marked continued clinical progress as we aim to advance the next wave of our FcRn leadership and expand our immunology pipeline beyond neurology. Together, these advancements reflect our Vision 2030 ambition and our commitment to reaching more patients globally. As we look ahead, we anticipate multiple important milestones before year-end that will further shape our next chapter of immunology innovation. Read our full Q3 2026 results report: https://bit.ly/4sf9Hw9 #EntrepreneurialScience
- For years, the default for enterprise software was to buy and only build when there was no alternative. AI-assisted engineering changed the math. Implementation now takes days instead of weeks, and the real work has moved to definition. With argenx, we compared build cost against full license cost over the same period. Building came out ahead, and the system now follows their process and their roadmap. If a process works the same everywhere, license it. If it’s specific to how you work, the comparison deserves a fresh look. More in
Open roles (8)
- Biostatistical Director - Stat Disease LeaderGhent · Oct 12, 2026
- Associate Director, Statistical Modeling and SimulationGhent · Oct 7, 2026
- Quality Compliance LeadGhent · Sep 30, 2026
- Medical Affairs and Evidence Generation Asset Lead –Executive DirectorBrussels · Sep 21, 2026
- Nurse Case Manager, OhioSep 14, 2026
- Head of Specialized SourcingGhent · Sep 11, 2026
- Project ToxicologistWavre · Sep 8, 2026
- Global DT Lead DevelopmentGhent · Sep 3, 2026
Alumni
Tim Van HauwermeirenChief Executive Officer
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.